Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders

Synergy between low molecular weight heparin and platelet aggregation inhibitors, providing a combination therapy for the prevention and treatment of various thromboembolic disorders

US Patent 6346517 · Granted Feb 12, 2002

Estimated economic value: $648,007,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2024
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2020
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2019
Nanocapsule containing a bioactive compound, and a method of reducing toxicity r2019
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2018
Composition of nanoformulated lycopene and method of using the composition2018
Imidazothiadiazole derivatives as protease activated receptor 4 (PAR4) inhibitor2018
Compositions of novel bone patch in bone and vascular regeneration2017
Nanoformulation of musk-derived bioactive ingredients for nanocosmetic applicati2017
Imidazothiadiazole and imidazopyrazine derivatives as protease activated recepto2017
Composition and method for sulfated non-anticoagulant low molecular weight hepar2017
Compositions and methods of natural products in nanoformulations for the prevent2013